Subscribe
shutterstock_1642888921_kira_yan
Kira Yan / Shutterstock.com
1 September 2020Big PharmaMuireann Bolger

European Commission's first deal for COVID-19 vaccine takes effect

The  European Commission’s first ever contract to secure a COVID-19 vaccine came into force on August 27, after it signed a deal with pharmaceutical company  AstraZeneca earlier this month.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
EC reveals plans for unitary SPC, compulsory licences
8 February 2022   The European Commission will unveil plans to make supplementary protection certificates more accessible and efficient for pharmaceutical companies to register and enforce by the end of March.
Big Pharma
EU reaches first COVID-19 vaccine deal
17 August 2020   The European Commission reached its first agreement to supply EU member states with an experimental COVID-19 vaccine with AstraZeneca late last week.
Americas
Associations lobby WHO to build COVID-19 IP pool
31 March 2020   Numerous associations and individuals have come together to ask the World Health Organization to build a global pool for IP rights related to the COVID-19 pandemic.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Europe
EC reveals plans for unitary SPC, compulsory licences
8 February 2022   The European Commission will unveil plans to make supplementary protection certificates more accessible and efficient for pharmaceutical companies to register and enforce by the end of March.
Big Pharma
EU reaches first COVID-19 vaccine deal
17 August 2020   The European Commission reached its first agreement to supply EU member states with an experimental COVID-19 vaccine with AstraZeneca late last week.
Americas
Associations lobby WHO to build COVID-19 IP pool
31 March 2020   Numerous associations and individuals have come together to ask the World Health Organization to build a global pool for IP rights related to the COVID-19 pandemic.

More on this story

Europe
EC reveals plans for unitary SPC, compulsory licences
8 February 2022   The European Commission will unveil plans to make supplementary protection certificates more accessible and efficient for pharmaceutical companies to register and enforce by the end of March.
Big Pharma
EU reaches first COVID-19 vaccine deal
17 August 2020   The European Commission reached its first agreement to supply EU member states with an experimental COVID-19 vaccine with AstraZeneca late last week.
Americas
Associations lobby WHO to build COVID-19 IP pool
31 March 2020   Numerous associations and individuals have come together to ask the World Health Organization to build a global pool for IP rights related to the COVID-19 pandemic.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB